Inspired by this gap in the literature, we hypothesize that sMRI can successfully predict amyloid and tau concentrations on a continuous scale in a regression problem and that the sMRI‐derived CSF proxy‐markers can be used to detect AD and predict future AD risk in the MCI population by using proxy‐markers from their baseline images only. This evidence concerns the gene MAPT and Alzheimer disease.